Product Pipeline

Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform. Our technology allows us to develop extended-release ODT or extended-release oral suspension formulations of existing extended-release medications.

Our technology is proven to work, with FDA’s approval of three different medications for the treatment of ADHD. Beyond our initial focus on ADHD, we believe patients with gastrointestinal (GI) and central nervous system (CNS) conditions could benefit from an extended-release ODT or extended-release liquid suspension medication.

 

Please see Important Safety Information, including Boxed WARNING for abuse and dependence, and Full Prescribing Information for Adzenys XR-ODT.

Please see Important Safety Information, including Boxed WARNING for abuse and dependence, and Full Prescribing Information for Cotempla XR-ODT.

Please see Important Safety Information, including Boxed WARNING for abuse and dependence, and Full Prescribing Information for Adzenys ER.

Please see Full Prescribing Information, including Boxed WARNING for Generic Tussionex.